- Conditions
- SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
- Interventions
- CRN09682
- Drug
- Lead sponsor
- Crinetics Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Duarte, California • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 12:13 AM EDT